CAR T cell immunotherapy for human cancer

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.

Source: ScienceNOW - March 22, 2018 Category: Science Authors: June, C. H., OConnor, R. S., Kawalekar, O. U., Ghassemi, S., Milone, M. C. Tags: Immunology, Medicine, Diseases special/review Source Type: news